Effects of Teriparatide in Patients with Osteoporosis in Clinical Practice: 42-Month Results During and After Discontinuation of Treatment from the European Extended Forsteo® Observational Study (ExFOS)

32Citations
Citations of this article
59Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

This study aimed to describe clinical outcomes in patients prescribed teriparatide and followed up for 18 months after stopping the drug in real-life conditions. The Extended Forsteo® Observational Study analysed incident clinical fractures in 6-month intervals using logistic regression with repeated measures. Changes in back pain (visual analogue scale) and health-related quality of life (HRQoL; EQ-5D questionnaire) were analysed using mixed models for repeated measures. Patients were analysed if they had a post-baseline visit, regardless of whether and for how long they took teriparatide. Of 1531 patients analysed (90.7% female, mean age: 70.3 years), 76 (5.0%) never took teriparatide. Median treatment duration was 23.6 months. The adjusted odds of clinical fracture decreased by 47% in the > 12- to 18-month treatment period (p = 0.013) compared with the first 6-month period, with no statistically significant reduction in the > 18- to 24-month interval. The clinical fracture rate remained stable during the 18 months’ post-teriparatide, when approximately 98% of patients took osteoporosis medication (51% bisphosphonates). Clinical vertebral fractures were reduced at every time period compared with the first 6 months. Adjusted mean back pain scores decreased and EQ-5D scores increased significantly at each post-baseline observation. In a real-life clinical setting, the risk of clinical fractures declined during 24 months of teriparatide treatment. This reduction was maintained 18 months after stopping teriparatide. In parallel, patients reported significant improvements in back pain and HRQoL. The results should be interpreted in the context of the non-controlled design of this observational study.

References Powered by Scopus

EuroQol: The current state of play

4878Citations
N/AReaders
Get full text

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

4177Citations
N/AReaders
Get full text

Romosozumab treatment in postmenopausal women with osteoporosis

1223Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Update on the safety and efficacy of teriparatide in the treatment of osteoporosis

68Citations
N/AReaders
Get full text

Photothermally triggered biomimetic drug delivery of Teriparatide via reduced graphene oxide loaded chitosan hydrogel for osteoporotic bone regeneration

61Citations
N/AReaders
Get full text

2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis

49Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Napoli, N., Langdahl, B. L., Ljunggren, Ö., Lespessailles, E., Kapetanos, G., Kocjan, T., … Marin, F. (2018). Effects of Teriparatide in Patients with Osteoporosis in Clinical Practice: 42-Month Results During and After Discontinuation of Treatment from the European Extended Forsteo® Observational Study (ExFOS). Calcified Tissue International, 103(4), 359–371. https://doi.org/10.1007/s00223-018-0437-x

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 17

77%

Professor / Associate Prof. 3

14%

Lecturer / Post doc 1

5%

Researcher 1

5%

Readers' Discipline

Tooltip

Medicine and Dentistry 17

65%

Nursing and Health Professions 6

23%

Pharmacology, Toxicology and Pharmaceut... 2

8%

Chemical Engineering 1

4%

Article Metrics

Tooltip
Mentions
News Mentions: 1
Social Media
Shares, Likes & Comments: 40

Save time finding and organizing research with Mendeley

Sign up for free